K71.7

Toxic liver disease with fibrosis and cirrhosis of liver

Toxic liver disease with fibrosis and cirrhosis of liver represents an advanced stage of hepatotoxicity where external chemical, pharmacological, or environmental agents have caused sustained hepatocellular injury, leading to irreversible architectural changes in the liver parenchyma. This condition is characterized by the widespread replacement of functional hepatic tissue with diffuse fibrous septa and regenerative nodules. Pathophysiologically, the persistent insult from a toxic agent triggers a chronic wound-healing response involving the activation of hepatic stellate cells, which synthesize an excessive extracellular matrix. Over time, this progression disrupts the liver's microvascular structure, increasing resistance to blood flow and culminating in portal hypertension. Clinically, it manifests as end-stage liver disease with significant risks of hepatic synthetic failure and life-threatening portal hypertensive complications. Accurate diagnosis requires establishing a temporal relationship with a specific hepatotoxin and the clinical or histopathological exclusion of other chronic liver etiologies such as viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), or primary biliary disease.

Clinical Symptoms

  • Jaundice (icterus) manifesting as yellowing of the skin and sclera
  • Ascites (abdominal fluid accumulation)
  • Hepatic encephalopathy presenting as confusion, altered consciousness, or asterixis
  • Pruritus (intense itching) from bile salt deposition
  • Gastrointestinal bleeding secondary to esophageal or gastric varices
  • Splenomegaly (enlargement of the spleen)
  • Spider angiomas on the trunk and upper extremities
  • Palmar erythema (reddening of the palms)
  • Caput medusae (visible periumbilical veins)
  • Easy bruising and prolonged bleeding times due to coagulopathy
  • Peripheral edema in the lower extremities
  • Profound fatigue and generalized malaise
  • Unintentional weight loss and muscle wasting (sarcopenia)

Common Causes

  • Chronic exposure to hepatotoxic medications such as Methotrexate or Isoniazid
  • Long-term use of specific anti-arrhythmics like Amiodarone
  • Industrial exposure to toxic chemicals including Carbon tetrachloride and Vinyl chloride
  • Ingestion of hepatotoxic herbal remedies or dietary supplements (e.g., Pyrrolizidine alkaloids, Kava kava)
  • Environmental toxins such as Aflatoxins produced by certain molds
  • Idiosyncratic drug-induced liver injury (DILI) where metabolic byproducts cause chronic inflammation
  • Interaction between alcohol consumption and hepatotoxic medications accelerating fibrogenesis

Documentation & Coding Tips

Specify the Toxic Agent and Temporal Relationship

Example: Patient with established Toxic liver disease with fibrosis and cirrhosis of liver due to chronic, high-dose Methotrexate exposure for refractory Psoriatic Arthritis. Last dose 3 weeks prior. Evidence of hepatotoxicity noted on serial LFTs with AST/ALT ratios suggesting toxic etiology rather than metabolic syndrome. Documentation supports K71.7 as the primary driver for current hepatic insufficiency.

Billing Focus: Documentation must identify the specific drug or external toxin (using T-codes for poisoning or adverse effects) to satisfy coding for toxic liver disease.

Differentiate Fibrosis Stage and Cirrhotic Complications

Example: Diagnosis: Toxic liver disease with fibrosis and cirrhosis of liver. Ultrasound reveals coarse echotexture and nodularity consistent with F4 fibrosis. Patient presents with Grade 2 ascites requiring paracentesis and esophageal varices without bleeding. The cirrhosis is directly attributed to long-term industrial solvent exposure (Carbon Tetrachloride).

Billing Focus: Identify the stage of fibrosis (F0-F4) to support the specificity of the K71.7 code and ensure associated complications like ascites (K65.2) are linked.

Document Management of Portal Hypertension and Sequelae

Example: Patient with K71.7 manifesting as portal hypertension and splenomegaly. Current MELD-Na score of 18. Patient is managed with Propranolol for primary prophylaxis of variceal bleeding and Spironolactone for fluid volume overload. Toxic insult identified as chronic ingestion of pyrrolizidine alkaloid-containing herbal supplements.

Billing Focus: Documentation of portal hypertension (K76.6) as a related condition supports the medical necessity for diagnostic procedures like EGD (43239).

Distinguish Between Poisoning, Adverse Effect, and Underdosing

Example: Clinical Note: Toxic liver disease with fibrosis and cirrhosis of liver resulting from an adverse effect of long-term Amiodarone therapy taken as prescribed for atrial fibrillation. This is not a poisoning event. Patient shows signs of jaundice and pruritus. Biopsy confirms drug-induced cirrhosis.

Billing Focus: Required use of additional codes from categories T36-T50 to identify the drug. Using an 'adverse effect' code versus a 'poisoning' code is critical for legal and billing accuracy.

Link Hepatic Encephalopathy when Present

Example: Patient hospitalized for Toxic liver disease with fibrosis and cirrhosis of liver presenting with Grade II hepatic encephalopathy. Asterixis noted on exam. Ammonia level 110 micromol/L. Trigger for decompensation identified as accidental acute-on-chronic acetaminophen toxicity. Treated with Lactulose and Rifaximin.

Billing Focus: Must document 'with hepatic encephalopathy' and indicate whether it is 'with coma' (K71.11) or 'without coma' (K71.10) if toxic liver disease is acute.

Relevant CPT Codes

Related Diagnoses

Hierarchy